PMC:7048180 / 1215-1659 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":178,"end":185},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T7","span":{"begin":39,"end":47},"obj":"Disease"},{"id":"T8","span":{"begin":138,"end":146},"obj":"Disease"},{"id":"T9","span":{"begin":230,"end":238},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":253,"end":256},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T10","span":{"begin":257,"end":258},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":178,"end":185},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."}

{"project":"LitCovid-sentences","denotations":[{"id":"T13","span":{"begin":0,"end":444},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."}

{"project":"LitCovid-PubTator","denotations":[{"id":"35","span":{"begin":117,"end":121},"obj":"Gene"},{"id":"47","span":{"begin":39,"end":47},"obj":"Species"},{"id":"48","span":{"begin":138,"end":146},"obj":"Species"},{"id":"49","span":{"begin":162,"end":171},"obj":"Species"},{"id":"50","span":{"begin":230,"end":238},"obj":"Species"},{"id":"51","span":{"begin":243,"end":252},"obj":"Species"},{"id":"52","span":{"begin":430,"end":439},"obj":"Species"},{"id":"58","span":{"begin":93,"end":99},"obj":"Chemical"}],"attributes":[{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"Gene:59272"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Tax:694009"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:694009"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Tax:2697049"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:694009"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:2697049"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD."}